Nong Xu

Dr. Nong Xu

First Affiliated Hospital Zhejiang University, Hangzhou, Zhejiang, China
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
CXCheng Xiao
Cheng Xiao
FSFang Song
Fang Song
YZYu Long Zheng
Yu Long Zheng
JLJiong Lv
Jiong Lv
QWQiang Feng Wang
Qiang Feng Wang
NXNong Xu
Nong Xu
Exosomes are small membranous vesicles that contain proteins, lipids, genetic material, and metabolites with abundant information from parental cells. Exosomes carry and deliver bioactive contents that can reprogram the functions of recipient cells and modulate the tumor microenvironment to induce pathological events through cell-to-cell communication and signal transduction. Tumor-derived exosomes (TDEs) in head and neck squamous cell carcinoma (HNSCC) are involved in most aspects of cancer initiation, invasion, progression, immunoregulation, therapeutic applications, and treatment resistance. In addition, HNSCC-derived exosomes can be used to obtain information on diagnostic and therapeutic biomarkers in circulating blood and saliva. Currently, the biology, mechanisms, and applications of TDEs in HNSCC are still unclear, and further research is required. In this review, we discuss various aspects of exosome biology, including exosomal components, exosomal biomarkers, and molecular mechanisms involved in immunoregulation, cancer metastasis, and therapy resistance. We also describe recent applications to update our understanding of exosomes in HNSCC.

19 June 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
HWHuan Wang
Huan Wang
YDYongfeng Ding
Yongfeng Ding
NLNing Li
Ning Li
LWLuntao Wu
Luntao Wu
YGYuan Gao
Yuan Gao
NXNong Xu
Nong Xu
Background: The prognostic value of neutrophil–lymphocyte ratio (NLR), platelet–lymphocyte ratio, and the combined NLR–PLR score in patients with stage IV gastric carcinoma (GC) has not yet been clarified. Therefore, this study aimed to explore the potential association of NLR, PLR, and NLR–PLR score with the prognosis of patients with stage IV GC. Methods: This retrospective study included 466 patients with GC diagnosed between 2010 and 2017. High NLR and high PLR were defined using the median values as the cutoff values. We then combined the NLR and PLR value and generated the NLR–PLR score as a new biomarker. Patients were divided into three groups according to their NLR–PLR score. Univariate and multivariate analyses were conducted to compare survival outcomes. Results: Median overall survival (OS) and progression-free survival (PFS) were 15.5 months (range, 0.7–96.8 months) and 6.7 months (range, 0.5–30.4 months), respectively. The NLR, PLR, and the NLR–PLR scores were correlated with clinical outcomes such as OS and PFS. Median OS for patients with NLR–PLR scores of 0, 1, and 2 was 22.5, 15.7, and 11.2 months, respectively. Median PFS for patients with these NLR–PLR scores of 0, 1, and 2 was 7.8, 7.1, and 5.2 months, respectively (P < 0.001). High NLR–PLR scores predicted poor survival in patients with stage IV GC (all P < 0.05). Conclusion: Our findings provide scientific evidence to support that the NLR–PLR score may be able to independently predict survival outcomes in patients with stage IV GC.

10 August 2020 in Cancers
Verified
Journal Article
Open access
PDF file
YCYanyan Chen
Yanyan Chen
QZQuan Zhou
Quan Zhou
HWHaiyong Wang
Haiyong Wang
WZWei Zhuo
Wei Zhuo
YDYongfeng Ding
Yongfeng Ding
LTLisong Teng
Lisong Teng
Gastric cancer (GC) is a leading cause of worldwide cancer-related death. Being a highly heterogeneous disease, the current treatment of GC has been suboptimal due to the lack of subtype-dependent therapies. Peritoneal dissemination (PD) is a common pattern of GC metastasis associated with poor prognosis. Therefore, it is urgently necessary to identify patients at high risk of PD. PD is found to be associated with Lauren diffuse type GC. Molecular profiling of GC, especially diffuse type GC, has been utilized to identify molecular alterations and has given rise to various molecular classifications, shedding light on the underlying mechanism of PD and enabling identification of patients at higher PD risk. In addition, a series of diagnositc and prognostic biomarkers of PD from serum, peritoneal lavages and primary GCs have been reported. This comprehensive review summarizes findings on the multi-omic characteristics of diffuse type GC, the clinical significance of updating molecular classifications of GC in association with PD risk and research advances in PD-associated biomarkers.

30 March 2024 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
LWLijuan Weng
Lijuan Weng
JZJianliang Zhou
Jianliang Zhou
SGShenchao Guo
Shenchao Guo
NXNong Xu
Nong Xu
RMRuishuang Ma
Ruishuang Ma
Triple-negative breast cancer (TNBC) is widely recognized as the most aggressive form of breast cancer, occurring more frequently in younger patients and characterized by high heterogeneity, early distant metastases and poor prognosis. Multiple treatment options have failed to achieve the expected therapeutic effects due to the lack of clear molecular targets. Based on genomics, transcriptomics and metabolomics, the multi-omics analysis further clarifies TNBC subtyping, which provides a greater understanding of tumour heterogeneity and targeted therapy sensitivity. For instance, the luminal androgen receptor subtype (LAR) exhibits responsiveness to anti-AR therapy, and the basal-like immune-suppressed subtype (BLIS) tends to benefit from poly (ADP-ribose) polymerase inhibitors (PARPis) and anti-angiogenic therapy. The efficacy of multi-dimensional combination therapy holds immense importance in guiding personalized and precision medicine for TNBC. This review offers a systematic overview of recent FuDan TNBC molecular subtyping and its role in the instruction of clinical precision therapy.

29 April 2019 in Journal of Applied Polymer Science
Verified
Journal Article
Closed access
PDF file
QLQiao Liu
Qiao Liu
LLLin Li
Lin Li
ZPZonglin Pan
Zonglin Pan
QDQiang Dong
Qiang Dong
NXNong Xu
Nong Xu
Tonghua WangTonghua Wang
Tonghua Wang

15 February 2022 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
YZYulong Zheng
Yulong Zheng
AMAnna Rachelle Austria Mislang
Anna Rachelle Austria Mislang
JCJermaine Coward
Jermaine Coward
RCRasha Cosman
Rasha Cosman
ACAdam Cooper
Adam Cooper
NXNong Xu
Nong Xu